BRIEF-翰森製藥稱奧萊泊肽注射液上市許可申請獲國家藥品監督管理局受理

路透中文

06/04

BRIEF-<a href="https://laohu8.com/S/03692">翰森製藥</a>稱奧萊泊肽注射液上市許可申請獲國家藥品監督管理局受理

路透北京6月4日 - Hansoh Pharmaceutical Group Company Ltd 3692.HK：

* 本集團創新藥奧萊泊肽注射液上市許可申請(NDA)獲中國國家藥品監督管理局(NMPA)受理，適用於肥胖或超重成人的長期體重管理

* 奧萊泊肽是一款本集團自主研發的每周一次給藥胰高血糖素樣肽-1(GLP-1)╱葡萄糖依賴性促胰島素多肽(GIP)雙受體激動劑（完）

公告全文，請點擊此處

(發稿劉珞焱)

((luoyan.liu@tr.com; +86 021 2083 0166;))

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2640805281"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640805281\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640805281?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-06-04 07:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640805281","market":"hk","top_or_hot":-1,"title":"BRIEF-翰森製藥稱奧萊泊肽注射液上市許可申請獲國家藥品監督管理局受理","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/03692\">翰森製藥</a>稱奧萊泊肽注射液上市許可申請獲國家藥品監督管理局受理</title></head><body><p><span>路透北京6月4日</span><span> - </span>Hansoh Pharmaceutical Group Company Ltd <span>3692.HK</span>：</p><p>* 本集團創新藥奧萊泊肽注射液上市許可申請(NDA)獲中國國家藥品監督管理局(NMPA)受理，適用於肥胖或超重成人的長期體重管理</p><p>* 奧萊泊肽是一款本集團自主研發的每周一次給藥胰高血糖素樣肽-1(GLP-1)╱葡萄糖依賴性促胰島素多肽(GIP)雙受體激動劑（完）</p><p>公告全文，請點擊此處</p><p> (發稿 劉珞焱)</p><p> ((luoyan.liu@tr.com; +86 021 2083 0166;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-翰森製藥稱奧萊泊肽注射液上市許可申請獲國家藥品監督管理局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-翰森製藥稱奧萊泊肽注射液上市許可申請獲國家藥品監督管理局受理\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2026-06-04 07:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/03692\">翰森製藥</a>稱奧萊泊肽注射液上市許可申請獲國家藥品監督管理局受理</title></head><body><p><span>路透北京6月4日</span><span> - </span>Hansoh Pharmaceutical Group Company Ltd <span>3692.HK</span>：</p><p>* 本集團創新藥奧萊泊肽注射液上市許可申請(NDA)獲中國國家藥品監督管理局(NMPA)受理，適用於肥胖或超重成人的長期體重管理</p><p>* 奧萊泊肽是一款本集團自主研發的每周一次給藥胰高血糖素樣肽-1(GLP-1)╱葡萄糖依賴性促胰島素多肽(GIP)雙受體激動劑（完）</p><p>公告全文，請點擊此處</p><p> (發稿 劉珞焱)</p><p> ((luoyan.liu@tr.com; +86 021 2083 0166;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nL4S42B22Y:1","article_id":"2640805281","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640805281","pubTimestamp":1780530016,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-翰森製藥稱奧萊泊肽注射液上市許可申請獲國家藥品監督管理局受理路透北京6月4日 - Hansoh Pharmaceutical Group Company Ltd 3692.HK：* 本集團創新藥奧萊泊肽注射液上市許可申請(NDA)獲中國國家藥品監督管理局(NMPA)受理，適用於肥胖或超重成人的長期體重管理* 奧萊泊肽是一款本集團自主研發的每周一次給藥胰高血糖素樣肽-1(GLP-1)╱葡萄糖依賴性促胰島素多肽(GIP)雙受體激動劑（完）公告全文，請點擊此處 (發稿 劉珞焱) ((luoyan.liu@tr.com; +86 021 2083 0166;))","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03692":"翰森制药","BK1191":"制药","BK1583":"高瓴概念","BK1589":"北水核心资产"},"translate_title":"BRIEF-Hansen Pharmaceuticals says the marketing authorization application for olepotide injection was accepted by the National Medical Products Administration","themeId":"37684715aaf54a73b9fe52ee56a263cc","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"BRIEF-翰森製藥稱奧萊泊肽注射液上市許可申請獲國家藥品監督管理局受理路透北京6月4日 - Hansoh Pharmaceutical Group Company Ltd 3692.HK：* 本集團創新藥奧萊泊肽注射液上市許可申請(NDA)獲中國國家藥品監督管理局(NMPA)受理，適用於肥胖或超重成人的長期體重管理* 奧萊泊肽是一款本集團自主研發的每周一次給藥胰高血糖素樣肽-1(GLP-1)╱葡萄糖依賴性促胰島素多肽(GIP)雙受體激動劑（完）公告全文，請點擊此處 (發稿 劉珞焱) ((luoyan.liu@tr.com; +86 021 2083 0166;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}